InspireMD, Inc.

Day range

$0.43 – $0.50

Open

$0.46

Prev close

$0.45

Volume

77.64K

Market cap

$21.04M

Shares out

46.49M

P/E

—

P/S

1.94

P/B

0.67

P/FCF

—

ROE

-166.6%

ROA

-117.6%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Executive officer departureJul 29, 2026

  On July 23, 2026, InspireMD, Inc. (the "Company") provided notice to Shane Gleason, the Company's Chief Commercial Officer, that his position has been eliminated. His last day of employment with the Company will be July 31, 2026.

• Listing deficiency noticeJul 23, 2026

  In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a compliance period of 180 calendar days, or until January 13, 2027, to regain compliance with Nasdaq Listing Rule 5550(a)(2). To regain compliance, the closing bid price of the Company's common stock must be at least $1.00 per share for a minimum of ten consecutive business days during the compliance period.

• Director departureJul 2, 2026

  On June 26, 2026, Mr. Raymond W. Cohen, a Class III member of the board of directors (the "Board") of InspireMD, Inc. (the "Company"), a member of the Audit Committee of the Board and a member of the Compensation Committee of the Board, tendered his resignation from the Board, effective July 1, 2026. Mr. Cohen's resignation from the Board was for personal considerations and not due to any disagreement with the Company, the Board or the management of the Company on any matter relating to the Company's operations, policies, practices or otherwise.

• Clinical trial resultsJun 11, 2026

  InspireMD Announces 30-Day Results from the CGUARDIANS II Clinical Trial of the CGuard Prime 80 cm Implant for Use in TCAR Procedures.

• Annual meeting resultsJun 3, 2026

  On June 3, 2026, the Company held its Annual Meeting. As of April 10, 2026, the record date for the Annual Meeting, there were 46,892,979 shares of common stock issued and outstanding and entitled to vote on the proposals presented at the Annual Meeting, of which 34,631,348, or 73.85%, were present in person or represented by proxy, which constituted a quorum. Based on the foregoing votes, Proposals 1 through 3 were approved.

Days to cover

1.0

Short interest

22.47K

Avg volume

70.55K

As of Sep 30, 2026 · reported to FINRA twice monthly.

• InspireMD Announces Amendments to Certain Series J and Series K Warrants, Providing Potential Gross Proceeds of Up to $11 Million
  positiveGlobeNewswire Inc.· Sep 21, 2026
• InspireMD Announces First Patient Enrolled in the CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System for Use in TCAR Procedures
  positiveGlobeNewswire Inc.· Jun 8, 2026
• InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Jan 20, 2026
• InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)
  positiveGlobeNewswire Inc.· Jan 12, 2026
• InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  neutralGlobeNewswire Inc.· Nov 21, 2025